Piomic Medical Secures Eurostars Financing for COMS® Blue
Piomic Medical secures Eurostars funding for COMS® Blue, advancing antibiotic-independent wound infection treatment with real-time diagnostics and digital health.
Written by
Published on
Zurich, Switzerland – 14 March 2025 – Piomic Medical, proudly announces that its new research and development project, COMS® Blue, has been awarded funding through Eureka and the Eurostars program. Eurostars is Europe’s largest international funding initiative for collaborative R&D projects driven by highly innovative SMEs, supporting the creation of new products, processes, or services for commercialization.
As one of 25 Swiss companies selected, Piomic Medical will collaborate closely with Fraunhofer IZM – a leading Research Institute for Reliability and Microintegration – and reanmo – a forward-thinking software company focused on user-centric digital solutions.
The goal of this project is to complement Piomic Medical’s COMS® treatment pipeline with an innovative solution for treatment and prevention of chronic and acute wound infections. COMS® Blue leverages real-time diagnostics, paired with digital health applications, ensuring a more targeted and personalized treatment of infections in wound care.
A pressing trend in recent years is the rise of antimicrobial Resistance (AMR) and Surgical Site Infections (SSI). Drug-resistant bacteria are increasingly common causes of SSIs, complicating treatment and outcomes.1
“We are honored by Eurostars’ recognition of our commitment to advancing both the treatment and diagnosis of infected wounds,” said Jari Kruth, CTO of Piomic Medical. “By combining our innovative platform technology with Fraunhofer IZM’s engineering expertise and reanmo’s software capabilities, we’re enhancing patient care while also taking direct aim at the urgent threat of AMR and rising incidence of SSIs.”
Recent global analyses put the pooled incidence of SSIs around 2.5% of surgical procedures, adding an average of 10 days to the postoperative hospital stay and more than $20,000 in hospital costs per admission.2,3 SSIs are associated with to a 2- to 11-fold increase in the risk of mortality with 75% of SSI-associated deaths directly attributable to the infection.3,4 These sobering statistics underscore the urgency for advanced, antibiotic-independent treatment options like COMS® Blue.
This project has received funding from Innosuisse and Bundesministerium für Bildung und Forschung through Eureka and the Eurostars program, which is co-funded by the European Commission as part of the European Partnership on Innovative SMEs. More information on Eurostars and Eureka can be found at eurekanetwork.org.
Important Regulatory Disclaimers
COMS® Blue is still under development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between COMS® Blue therapy and investigations with the COMS® One therapy system in Europe or the United States.
Literature References
1. Monk EJM, Jones TPW, Bongomin F, Kibone W, Nsubuga Y, et al. (2024) Antimicrobial resistance in bacterial wound, skin, soft tissue and surgical site infections in Central, Eastern, Southern and Western Africa: A systematic review and meta-analysis. PLOS Global Public Health 4(4): e0003077.
2. Zimlichman, E, Henderson D, Tamir O, et al., “Health care-associated infections. a meta-analysis of costs and financial impact on the US health care system”. JAMA Intern Med, 173(22):(2013): 2039-46.
3. Ban, KA, Minei JP, Laronga C, et al., “American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update”. J Am Coll Surg, 224(1): (2017): 59-74.
4. Awad, SS, “Adherence to surgical care improvement project measures and postoperative surgical site infections”. Surgical Infect (Larchmt), 13(4): (2012): 234-7.